Complement is a major innate defense system that protects the intravascular space from microbial invasion. Complement activation results in the assembly of C3 convertases, serine proteases that cleave complement protein C3, generating bioactive fragments C3a and C3b. The complement response is rapid and robust, largely due to a positive feedback regulatory loop mediated by alternative pathway (AP) C3 convertase. C3 nephritic factors (C3NEFs) are autoantibodies that stabilize AP convertase, resulting in uncontrolled C3 cleavage, which, in principle, can promote critical tissue injury similar to that seen in certain renal conditions. Investigations of C3NEFs are hampered by a challenging issue: each C3NEF is derived from a different donor source, and there is no method to compare one C3NEF to another. We have identified a widely available mouse anti-C3 mAb that, similar to many C3NEFs, can stabilize functional AP convertase in a form resistant to decay acceleration by multiple complement regulators. The antibody requires the presence of properdin to confer convertase stability, and hampers the activity of Salp20, a tic salivary protein that accelerates convertase dissociation by displacing properdin from the convertase complex. This mAb can serve as an urgently needed standard for the investigation of C3NEFs. This study also provides novel insights into the dynamics of AP convertase.
Get full access to this article
View all access options for this article.
References
1.
RicklinD, HajishengallisG, YangK, et al.Complement: A key system for immune surveillance and homeostasis. Nat Immunol, 2010; 11(9):785–797.
2.
FearonDT, LocksleyRM. The instructive role of innate immunity in the acquired immune response. Science, 1996; 272:50–54.
3.
CarrollMC. The complement system in regulation of adaptive immunity. Nat Immunol, 2004; 5(10):981–986.
4.
KemperC, AtkinsonJP. T-cell regulation: With complements from innate immunity. Nat Rev Immunol, 2007; 7(1):9–18.
5.
OllertMW, KadlecJV, DavidK, et al.Antibody-mediated complement activation on nucleated cells. A quantitative analysis of the individual reaction steps. J Immunol, 1994; 153(5):2213–2221.
6.
FearonDT, AustenKF. Properdin: Binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med, 1975; 142:856–863.
7.
MedicusRG, GotzeO, Muller-EberhardHJ. Alternative pathway of complement: Recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway. J Exp Med, 1976; 144:1076–1093.
8.
LiszewskiMK, AtkinsonJP. Complement regulators in human disease: Lessons from modern genetics. J Intern Med, 2015; 277(3):294–305.
9.
DahaMR, FearonDT, AustenKF. C3 nephritic factor (C3NeF): Stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol, 1976; 116(1):1–7.
10.
WeilerJM, DahaMR, AustenKF, et al.Control of the amplification convertase of complement by the plasma protein Beta 1H. Proc Natl Acad Sci USA, 1976; 73:3268–3272.
11.
Davis IIIAE, ZieglerJB, GelfandEW, et al.Heterogeneity of nephritic factor and its identification as an immunoglobulin. Proc Natl Acad Sci U S A, 1977; 74(9):3980–3983.
12.
NorisM, DonadelliR, RemuzziG. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy. Pediatr Nephrol, 2019; 34(8):1311–1323.
13.
ZhangY, MeyerNC, WangK, et al.Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol, 2012; 7(2):265–274.
14.
Paixao-CavalcanteD, Lopez-TrascasaM, SkattumL, et al.Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation. Kidney Int, 2012; 82(10):1084–1092.
15.
HourcadeDE, MitchellLM, OglesbyTJ. Mutations of the type A domain of complement factor B that promote high-affinity C3b-binding. J Immunol, 1999; 162(5):2906–2911.
16.
WhaleyK.Measurement of Complement. In: Methods in Complement for Clinical Immunologists. (Whaley K. ed.) Churchill Livingstone: New York; 1985; pp. 77–139.
17.
TanumaY, OhiH, HatanoM. Monoclonal anti-human C3d antibodies: Stabilization of the alternative pathway C3 convertase. Immunology, 1989; 68(4):445–448.
18.
ThurmanJM, KulikL, OrthH, et al.Detection of complement activation using monoclonal antibodies against C3d. J Clin Invest, 2013; 123(5):2218–2230.
19.
ClardyCW, ForristalJ, StrifeCF, et al.A properdin dependent nephritic factor slowly activating C3, C5, and C9 in membranoproliferative glomerulonephritis, types I and III. Clin Immunol Immunopathol, 1989; 50(3):333–347.
20.
TanumaY, OhiH, HatanoM. Two types of C3 nephritic factor: Properdin-dependent C3NeF and properdin-independent C3NeF. Clin Immunol Immunopathol, 1990; 56(2):226–238.
21.
MichelsM, van de KarN, van den BosRM, et al.Novel assays to distinguish between properdin-dependent and properdin-independent C3 nephritic factors provide insight into properdin-inhibiting therapy. Front Immunol, 2019; 10:1350.
22.
TysonK, ElkinsC, PattersonH, et al.Biochemical and functional characterization of Salp20, an Ixodes scapularis tick salivary protein that inhibits the complement pathway. Insect Mol Biol, 2007; 16(4):469–479.
23.
TysonKR, ElkinsC, de SilvaAM. A novel mechanism of complement inhibition unmasked by a tick salivary protein that binds to properdin. J Immunol, 2008; 180(6):3964–3968.
24.
MollnesTE, NgYC, PetersDK, et al.Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro. Clin Exp Immunol, 1986; 65(1):73–79.
25.
NgYC, PetersDK. C3 nephritic factor (C3NeF): Dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase. Clin Exp Immunol, 1986; 65(2):450–457.
26.
SchwertzR, RotherU, AndersD, et al.Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: A long-term follow-up. Pediatr Allergy Immunol, 2001; 12(3):166–172.
27.
GewurzAT, ImherrSM, StraussS, et al.C3 nephritic factor and hypocomplementaemia in a clinically healthy individual. Clin Exp Immunol, 1983; 54(1):253–258.
28.
SpitzerRE, StitzelAE, TsokosGC. Evidence that production of autoantibody to the alternative pathway C3 convertase is a normal physiologic event. J Pediatr, 1990; 116(5):S103–S108.
29.
FornerisF, WuJ, XueX, et al.Regulators of complement activity mediate inhibitory mechanisms through a common C3b-binding mode. EMBO J, 2016; 35(10):1133–1149.
30.
WuJ, WuYQ, RicklinD, et al.Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat Immunol, 2009; 10(7):728–733.
31.
RooijakkersSH, WuJ, RuykenM, et al.Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nat Immunol, 2009; 10(7):721–727.
32.
PedersenDV, RoumeninaL, JensenRK, et al.Functional and structural insight into properdin control of complement alternative pathway amplification. EMBO J, 2017; 36(8):1084–1099.
33.
van den BosRM, PearceNM, GrannemanJ, et al.Insights into enhanced complement activation by structures of properdin and its complex with the C-terminal domain of C3b. Front Immunol, 2019; 10:2097.
NishidaN, WalzT, SpringerTA. Structural transitions of complement component C3 and its activation products. Proc Natl Acad Sci U S A, 2006; 103(52):19737–19742.
36.
AlcorloM, TortajadaA, Rodriguez de CordobaS, et al.Structural basis for the stabilization of the complement alternative pathway C3 convertase by properdin. Proc Natl Acad Sci U S A, 2013; 110(33):13504–13509.
37.
RodriguezE, NanR, LiK, et al.A revised mechanism for the activation of complement C3 to C3b: A molecular explanation of a disease-associated polymorphism. J Biol Chem, 2015; 290(4):2334–2350.
